Search Results - (Author, Cooperation:L. T. Vahdat)

Showing 1 - 2 results of 2, query time: 0.11s Refine Results
  1. 1
    Staff View
    Publication Date:
    2015-11-13
    Publisher:
    Nature Publishing Group (NPG)
    Print ISSN:
    0028-0836
    Electronic ISSN:
    1476-4687
    Topics:
    Biology
    Chemistry and Pharmacology
    Medicine
    Natural Sciences in General
    Physics
    Keywords:
    Animals ; Antineoplastic Agents, Alkylating/pharmacology/therapeutic use ; Apoptosis/drug effects ; Cell Lineage ; Cell Proliferation/drug effects ; Cell Tracking ; Cyclophosphamide/pharmacology/therapeutic use ; Disease Models, Animal ; Disease Progression ; *Drug Resistance, Neoplasm/drug effects/genetics ; *Epithelial-Mesenchymal Transition/drug effects/genetics ; Female ; Lung Neoplasms/drug therapy/genetics/*pathology/*secondary ; Male ; Mammary Neoplasms, Experimental/*drug therapy/genetics/*pathology ; Mice ; MicroRNAs/genetics ; Neoplasm Metastasis/drug therapy/genetics/*pathology ; Reproducibility of Results
    Published by:
    http://www.nature.com/

    Latest Papers from Table of Contents or Articles in Press
  2. 2
    Staff View
    ISSN:
    1569-8041
    Keywords:
    bilateral facial nerve palsy ; neurotoxicity ; paclitaxel
    Source:
    Springer Online Journal Archives 1860-2000
    Topics:
    Medicine
    Notes:
    Abstract Bilateral facial nerve palsy is an uncommon occurrence. We describe a case of bilateral facial nerve palsy secondary to a single cycle of high-dose paclitaxel therapy (825 mg/m2), in a woman with breast cancer. Prior to her high-dose therapy, she had a residual grade 2 peripheral neuropathy following treatment with ten cycles of standard-dose paclitaxel (total dose 3200 mg). The features of the peripheral neuropathy due to standard-dose paclitaxel, which can be both motor and sensory, are well described. Cumulative paclitaxel dose is considered a risk factor for development of the neuropathy. Although facial nerve palsy secondary to paclitaxel is not previously reported, other cranial nerve toxicity has been described. Consistent with reports of the reversibility of paclitaxel-induced peripheral neuropathy, the facial nerve palsies in our patient resolved over 23 months. Ongoing studies of high-dose paclitaxel warrant close attention to its cumulative neurotoxic effects, particularly in patients previously treated with neurotoxic chemotherapy.
    Type of Medium:
    Electronic Resource
    URL:
    http://dx.doi.org/10.1023/A:1008380800394

    Articles: DFG German National Licenses